Professor Richard Houlston from The Institute of Cancer Research led the major international collaboration comparing the DNA of 1,633 meningioma patients and 2,464 healthy controls, using a technique known as a genome-wide association study.
Relatives of people with meningiomas are three times more likely to develop the disease but little is known about what increases their risk. A small proportion of meningiomas are linked to four rare genetic diseases called neurofibromatiosis type-2, Coden, Werner and Gorlin symdromes.
Professor Houlston said: “We knew that people with certain rare inherited diseases are more likely to develop meningiomas. Although these inherited diseases significantly increase the chance of getting this type of brain cancer, they are so rare that they account for a very small proportion of the increased risk among relatives of people with meningiomas. Our study begins to shed light on the biggest part of the inherited risk.
“The genetic region we’ve found is very closely linked with two genes called AF10 and MLLT10, which we know are involved in the development of leukaemia. We can’t say at this stage whether the diseases are linked or even if the two genetic regions interact, but we’ll be looking at this in our follow up studies.”
More than 4,500 people are diagnosed with malignant brain tumours in the UK each year. Meningiomas account for around a quarter of these, but little is known about the cause of the disease, which tends to mostly affect older people and women.
The tumours tend to grow slowly in the tissues of the brain or spinal cord and as a result do not respond well to chemotherapy and cannot always be safely removed by surgery.
Dr Julie Sharp, senior science information manager at Cancer Research UK, said: “Brain tumours are usually more difficult to treat because of the sensitive position of the tumour. As a result of this, survival rates have remained quite low.
“Studies like this are important in helping us understand more about the way brain tumours develop and this research has already given scientists another lead to follow to learn more about the disease.”
For media enquiries please contact Rachel Gonzaga in the Cancer Research UK press office on 020 3469 8300 or, out-of-hours, the duty press officer on 07050 264 059.
Notes to editors:
* Common variation at 10p12.31 near MLLT10 influences meningioma. Dobbins et al. Nature Genetics.
The Institute of Cancer Research (ICR)
- The ICR is Europe’s leading cancer research centre
- The ICR has been ranked the UK’s top academic research centre, based on the results of the Higher Education Funding Council’s Research Assessment Exercise
- The ICR works closely with partner The Royal Marsden NHS Foundation Trust to ensure patients immediately benefit from new research. Together the two organisations form the largest comprehensive cancer centre in Europe
- The ICR has charitable status and relies on voluntary income
- As a college of the University of London, the ICR also provides postgraduate higher education of international distinction
- Over its 100-year history, the ICR’s achievements include identifying the potential link between smoking and lung cancer which was subsequently confirmed, discovering that DNA damage is the basic cause of cancer and isolating more cancer-related genes than any other organisation in the world
About Cancer Research UK
Cancer Research UK is the world’s leading cancer charity dedicated to saving lives through research.
• The charity’s groundbreaking work into the prevention, diagnosis and treatment of cancer has helped save millions of lives. This work is funded entirely by the public.
• Cancer Research UK has been at the heart of the progress that has already seen survival rates double in the last forty years.
• Cancer Research UK supports research into all aspects of cancer through the work of over 4,000 scientists, doctors and nurses.
• Together with its partners and supporters, Cancer Research UK’s vision is to beat cancer.
For further information about Cancer Research UK’s work or to find out how to support the charity, please call 020 7121 6699 or visit www.cancerresearchuk.org